γ-Acetylenic GABA in Tardive Dyskinesia

Daniel Casey, Jes Gerlach, Gerhard Magelund, Torben Rosted Christensen

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Brain γ-aminobutyric acid (GABA) has been proposed to play a role in the modulation of extrapyramidal motor function. The effects of increasing brain GABA with γ-acetylenic GABA (GAG), a drug that inhibits GABA transaminase, were evaluated in ten patients with stable tardive dyskinesia during a blind placebo-controlled trial. Drug effects during active treatment and two placebo periods were evaluated by scoring randomly sequenced videotapes of tardive dyskinesia and parkinsonian symptoms recorded weekly during a standardized examination. Tardive dyskinesia was significantly reduced, and preexisting parkinsonism increased slightly. The largest decrease in tardive dyskinesia symptoms occurred in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. Prolactin values increased but growth hormone values were unchanged. Psychiatric symptoms were also unchanged during GAG treatment.

Original languageEnglish (US)
Pages (from-to)1376-1379
Number of pages4
JournalArchives of General Psychiatry
Volume37
Issue number12
DOIs
StatePublished - 1980

Fingerprint

gamma-Aminobutyric Acid
Placebos
4-Aminobutyrate Transaminase
Aminobutyrates
Videotape Recording
Brain
Parkinsonian Disorders
Pharmaceutical Preparations
Prolactin
Antipsychotic Agents
Growth Hormone
Psychiatry
Tardive Dyskinesia
Dopamine
Placebo
Therapeutics
Controlled
Interaction
Dose
Hormones

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Casey, D., Gerlach, J., Magelund, G., & Christensen, T. R. (1980). γ-Acetylenic GABA in Tardive Dyskinesia. Archives of General Psychiatry, 37(12), 1376-1379. https://doi.org/10.1001/archpsyc.1980.01780250062007

γ-Acetylenic GABA in Tardive Dyskinesia. / Casey, Daniel; Gerlach, Jes; Magelund, Gerhard; Christensen, Torben Rosted.

In: Archives of General Psychiatry, Vol. 37, No. 12, 1980, p. 1376-1379.

Research output: Contribution to journalArticle

Casey, D, Gerlach, J, Magelund, G & Christensen, TR 1980, 'γ-Acetylenic GABA in Tardive Dyskinesia', Archives of General Psychiatry, vol. 37, no. 12, pp. 1376-1379. https://doi.org/10.1001/archpsyc.1980.01780250062007
Casey, Daniel ; Gerlach, Jes ; Magelund, Gerhard ; Christensen, Torben Rosted. / γ-Acetylenic GABA in Tardive Dyskinesia. In: Archives of General Psychiatry. 1980 ; Vol. 37, No. 12. pp. 1376-1379.
@article{82692a98a69e4105b776a344316270ab,
title = "γ-Acetylenic GABA in Tardive Dyskinesia",
abstract = "Brain γ-aminobutyric acid (GABA) has been proposed to play a role in the modulation of extrapyramidal motor function. The effects of increasing brain GABA with γ-acetylenic GABA (GAG), a drug that inhibits GABA transaminase, were evaluated in ten patients with stable tardive dyskinesia during a blind placebo-controlled trial. Drug effects during active treatment and two placebo periods were evaluated by scoring randomly sequenced videotapes of tardive dyskinesia and parkinsonian symptoms recorded weekly during a standardized examination. Tardive dyskinesia was significantly reduced, and preexisting parkinsonism increased slightly. The largest decrease in tardive dyskinesia symptoms occurred in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. Prolactin values increased but growth hormone values were unchanged. Psychiatric symptoms were also unchanged during GAG treatment.",
author = "Daniel Casey and Jes Gerlach and Gerhard Magelund and Christensen, {Torben Rosted}",
year = "1980",
doi = "10.1001/archpsyc.1980.01780250062007",
language = "English (US)",
volume = "37",
pages = "1376--1379",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - γ-Acetylenic GABA in Tardive Dyskinesia

AU - Casey, Daniel

AU - Gerlach, Jes

AU - Magelund, Gerhard

AU - Christensen, Torben Rosted

PY - 1980

Y1 - 1980

N2 - Brain γ-aminobutyric acid (GABA) has been proposed to play a role in the modulation of extrapyramidal motor function. The effects of increasing brain GABA with γ-acetylenic GABA (GAG), a drug that inhibits GABA transaminase, were evaluated in ten patients with stable tardive dyskinesia during a blind placebo-controlled trial. Drug effects during active treatment and two placebo periods were evaluated by scoring randomly sequenced videotapes of tardive dyskinesia and parkinsonian symptoms recorded weekly during a standardized examination. Tardive dyskinesia was significantly reduced, and preexisting parkinsonism increased slightly. The largest decrease in tardive dyskinesia symptoms occurred in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. Prolactin values increased but growth hormone values were unchanged. Psychiatric symptoms were also unchanged during GAG treatment.

AB - Brain γ-aminobutyric acid (GABA) has been proposed to play a role in the modulation of extrapyramidal motor function. The effects of increasing brain GABA with γ-acetylenic GABA (GAG), a drug that inhibits GABA transaminase, were evaluated in ten patients with stable tardive dyskinesia during a blind placebo-controlled trial. Drug effects during active treatment and two placebo periods were evaluated by scoring randomly sequenced videotapes of tardive dyskinesia and parkinsonian symptoms recorded weekly during a standardized examination. Tardive dyskinesia was significantly reduced, and preexisting parkinsonism increased slightly. The largest decrease in tardive dyskinesia symptoms occurred in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. Prolactin values increased but growth hormone values were unchanged. Psychiatric symptoms were also unchanged during GAG treatment.

UR - http://www.scopus.com/inward/record.url?scp=0019218652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019218652&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1980.01780250062007

DO - 10.1001/archpsyc.1980.01780250062007

M3 - Article

C2 - 6108751

AN - SCOPUS:0019218652

VL - 37

SP - 1376

EP - 1379

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 12

ER -